

The Directors
Amryt Pharma plc
Dept 920a
196 High Road
Wood Green
London N22 8HH
United Kingdom

27 August 2019

Dear Sirs

Amryt Pharma plc (the “Company”) – Consent Letter

We, MTS Securities LLC, refer to the admission document of the Company dated 27 August 2019 relating to, among other things, the acquisition of Aegerion Pharmaceuticals, Inc., the scheme of arrangement and the applications for admission of the entire issued share capital of a new holding company of the Company to AIM and the Euronext Growth Market (the “**Admission Document**”).

We hereby give our consent to the inclusion in the Admission Document of its joint report with Shore Capital and Corporate Limited relating to the Quantified Financial Benefit Statement, as contained in Part C of Part 14 of the Admission Document, a copy of which is appended to this letter and initialled by us for the purpose of identification.


In addition, we consent to the inclusion in the Admission Document of the references to our name generally in the form and context in which they are included, as shown in the enclosed proof of the Admission Document initialled by us for the purpose of identification.

Our consent is required by:

- (a) Annex 1 item 1.3 of Commission Delegated Regulation (EU) No 2019/980 as applied by paragraph (a) of Schedule Two to the AIM Rules for Companies and paragraph (a) of Schedule Two of Chapter 5 of the Euronext Growth Market Rules for Companies; and
- (b) Rule 23.2(b) of the City Code on Takeovers and Mergers,

and, in each case, is given for the purpose of complying with those provisions and for no other purpose.

Yours faithfully,



.....

MTS Securities LLC